Article

FDA Announces Worldwide Recall of Left Ventricular Assist System Controller

Author(s):

Thoratec is initiating a worldwide recall of their HeartMate II Left Ventricular Assist System.

Thoratec Corp. has initiated a worldwide recall of its left ventricular assist system (LVAS) back-up system controller due to insufficient labelling and training for patients who updated from an older version of the controller, the US Food and Drug Administration (FDA) announced today.

The recalled Pocket System Controller connects an implanted HeartMate II LVAS pump through a driveline under the skin. The EPC controller helps power the LVAS system, which circulates blood throughout the body when the heart is too weak to do so sufficiently on its own.

Thoratec has recalled the system after receiving 5 reports of serious injury and 4 reports of death associated with updating to the back-up system controller. The patients who were affected by the switch did not receive adequate training on how to connect the new controller, which differs in design from the older model.

The controller can be operated by batteries or a connection to a main power supply, but without a proper connection, the device cannot function. Instructions for switching from one controller to a back-up system in case of alarm or malfunction are currently included with the system.

Related Videos
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.